ACP Internist provides news and information for internal medicine physicians about the practice of medicine and reports on the policies, products, and activities of ACP.
This regulatory update covers dapaglifozin (Farxiga) a sodium-glucose co-transporter 2 inhibitor, to treat diabetes, and umeclidinium and vilanterol inhalation (Anoro Ellipta) for maintenance of chronic obstructive pulmonary disease.
Regular primary care providers treat diabetic patients more proactively than covering physicians or midlevel providers, shown by an increase...
This regulatory update covers a recall of a compounding pharmacy's products due to mold and approval of a sodium-glucose co-transporter for diabetes.
This update covers approval of a sodium-glucose co-transporter 2 inhibitor for diabetes, a once-daily long-acting beta-adrenergic agonist (LABA) for chronic obstructive pulmonary disease (COPD), and a new intravenous drug for bacterial skin and
QD: News Every Day--'Made in America' fast food associated with heart disease, diabetes : ACP Internist
The export of American fast food restaurants to Singapore was associated with a spike in diabetes and cardiovascular diseases there, a study...
This update also covers a risk evaluation and mitigation strategy for liraglutide and approval of a new PCSK9 inhibitor.
I needn't belabor the news that Paula Deen, a celebrity chef on TV (that was news to me; nobody tells me anything) "came out" with her Type ...
This update covers a warning on sodium-glucose cotransporter-2 inhibitors and approval of a trivalent vaccine for the prevention of seasonal influenza in people age 65 years and older.
A summary of approvals, recalls, warnings and alerts digested by ACP Internist from the Food and Drug Administration's alerts.